Mélanie RochÂ
PhD PharmD, University of Lyon
Research Fellow
Melanie Roch [at] unige.ch
https://orcid.org/0000-0001-6485-8434Mélanie is originally from Évian, France. She earned a Doctorate in Pharmacy from the University of Lyon, where she trained in clinical microbiology and conducted research at the French National Reference Center for Staphylococci. Following this, she moved to the Houston Methodist Research Institute in Texas, where she worked as a postdoctoral fellow in Dr. A. Rosato’s group. In 2017, Mélanie joined Dr. W. Kelley’s lab at the University of Geneva, focusing on the molecular mechanisms of antibiotic resistance in Staphylococcus aureus. She was promoted to Maître-Assistante in 2021. During this period, she also collaborated closely with Dr. Diego Andrey on Klebsiella pneumoniae. In 2024, Mélanie joined the Kline lab to investigate the mechanisms contributing to antibiotic resistance in Enterococci. In addition to her research, she enjoys teaching medical microbiology. Outside the lab, you can often find Mélanie exploring the mountains, skiing or enjoying other outdoor activities.
| 1. | Contributions of Long-Read Sequencing for the Detection of Antimicrobial Resistance. Sierra R, Roch M, Moraz M, Prados J, Vuilleumier N, Emonet S, Andrey DO. Pathogens. 2024 Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. Roch M, Sierra R, Andrey DO. Clin Microbiol Infect. 2022 (Review) | |
| 2. | Characterization of Amino Acid Substitution W20S in MgrB Involved in Polymyxin Resistance in Klebsiella pneumoniae. Roch M, Martins WM, Sierra R, Gales AC, Andrey DO. Microbiol Spectr. 2022 | |
| 3. | A New Mutation in mgrB Mediating Polymyxin Resistance in Klebsiella variicola. Lenzi MH, Martins W, Roch M, Ramos PL, Sands K, Cayo R, Walsh TR, Andrey DO, Gales AC. Int J Antimicrob Agents. 2021 | |
| 4. | The Role of ArlRS and VraSR in Regulating Ceftaroline Hypersusceptibility in Methicillin-Resistant Staphylococcus aureus. Villanueva M, Roch M, Lasa I, Renzoni A, Kelley WL. Antibiotics 2021 | |
| 5. | Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA. Varela MC, Roch M, Taglialegna A, Long SW, Saavedra MO, Rose WE, Davis JJ, Hoffman LR, Hernandez RE, Rosato RR, Rosato AE. Commun Biol. 2020 | |
| 6. | Vertical and horizontal dissemination of an IncC plasmid harbouring rmtB 16S rRNA methylase gene, conferring resistance to plazomicin, among invasive ST258 and ST16 KPC-producing Klebsiella pneumoniae. Roch M, Sierra R, Sands K, Martins W, Schrenzel J, Walsh TR, Gales AC, Andrey DO. J Glob Antimicrob Resist. 2020 | |
| 7. | Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients. Roch M, Varela MC, Taglialegna A, Rosato AE. J Antimicrob Chemother. 2020 | |
| 8. | Efficacy of newly generated short antimicrobial cationic lipopeptides against methicillin-resistant Staphylococcus aureus (MRSA). Greber KE, Roch M, Rosato MA, Martinez MP, Rosato AE. Int J Antimicrob Agents. 2020 | |
| 9. | Thermosensitive PBP2a requires extracellular folding factors PrsA and HtrA1 for Staphylococcus aureus MRSA beta-lactam resistance. Roch M, Lelong E, Panasenko OO, Sierra R, Renzoni A, Kelley WL. Commun Biol. 2019 | |
| 10. | Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus. Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen B. Antimicrob Agents Chemother. 2018 | |
| 11. | Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients. Roch M, Varela MC, Taglialegna A, Rose WE, Rosato AE. Activity of Telavancin against Antimicrob Agents Chemother 2018 | |
| 12. | Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost. Roch M, Gagetti P, Davis J, Ceriana P, Errecalde L, Corso A, Rosato AE. Front Microbiol 2017 |
